## Nexus Surgical and Medicare Limited

(Formerly known as Nexus Commodities and Technologies Limited)
CIN - L33100MH1992PLC328367

Registered Office: Gala No. 4, Saarthak, Building No. 1, Square Industrial Park, Tungarphata, Vasai (East), Palghar - 401 208

Email: nexuscomm92@gmail.com Tel. No.: +91 8433598185

Website: www.nexusmed.co.in

Date: 14th February, 2022

To,
BSE Limited
Corporate Relation Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Code - 538874

Sub: Outcome of Board Meeting held on Monday, 14th February, 2022

Dear Sir / Madam,

We would like to inform you that the meeting of the Board of Directors of Nexus Surgical and Medicare Limited was held on Monday, 14<sup>th</sup> February, 2022 at 03:30 p.m. at the Registered Office of the Company situated at Gala No. 4, Saarthak, Building No. 1, Square Industrial Park, Tungarphata, Vasai (East), Palghar - 401 208 and transacted the following business:

1. The Board of Directors of the Company has approved the unaudited quarterly financial results of the Company for the quarter and nine months ended 31st December, 2021. A copy of the same alongwith Limited Review Report on the said results is enclosed herewith for your kind perusal.

The meeting commenced at 03:30 p.m. and concluded at 04:00 p.m.

Kindly take the same on your records.

Thanking you.

Yours faithfully,

For Nexus Surgical and Medicare Limited

(Formerly known as Nexus Commodities and Technologies Limited)

Ram Swaroop Joshi DIN: 07184085

Whole-time Director

\* bolimica \* bolimica

Encl: as above

## **Nexus Surgical and Medicare Limited**

(Formerly known as Nexus Commodities and Technologies Limited)

Statement of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2021

(Rs. in lakhs, except earning per share data)

Particulars		Quarter Ended on			Nine Months Ended on	
	Dec 31, 2021	Sep 30, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020	March 31, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income	T					
Sales	176.50	40.00	-	239.50	336.42	374.42
Other Income	0.30	0.12	0.53	1.03	0.71	0.84
Total Income	176.80	40.12	0.53	240.53	337.14	375.27
Expenses						
Purchase of stock-in-trade	38.32	-	-	38.32	102.47	102.47
Change in inventories of stock-in-trade	(38.32)	-	-	(38.32)	-	-
Employee benefits expense	5.34	4.32	6.15	17.16	17.95	31.90
Depreciation and amortization expense	0.07	0.07	0.07	0.20	0.20	0.26
Other expense	111.54	15.57	22.91	127.96	169.81	223.59
Total Expenses	116.96	19.96	29.13	145.32	290.43	358.23
Profit/(loss) before Exceptional Item and Tax	59.85	20.16	(28.60)	95.21	46.70	17.04
Exceptional Item Income/(Loss)	-			-	-	-
Profit/(loss) before tax	59.85	20.16	(28.60)	95.21	46.70	17.04
Tax expenses	22.60	(1.14)	(7.20)	24.09	11.75	1.64
Profit/(loss) for the period	37.25	21.30	(21.40)	71.12	34.95	15.40
Other comprehensive income (OCI), net of income tax			-			
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Items that will be reclassified to profit or loss	-	<u> </u>	<u> </u>			-
Total other comprehensive income, net of income tax	-	-			<u> </u>	-
Total other comprehensive income for the period	37.25	21.30	(21.40)	71.12	34.95	15.40
		5				
Paid-up Equity Share Capital (Equity shares of Rs. 10 each)	547.19	547.19	547.19	547.19	547.19	547.19
Other Equity						(557.99)
Basic and Diluted Earning Per Share (not annualized)	0.68	0.39	(0.39)	1.30	0.64	0.28

## Notes:

- 1 The above Financial result were reviewed by the audit committee thereafter approved and recorded by the Board of Directors at their meeting held on February 14, 2022.
- 2 The above results have been reviewed by the Statutory Auditor of the Company.
- 3 The Company is engaged primarily in the trading business and accordingly there are no separate reportable segments as per Ind AS 108 dealing with Operating Segment
- 4 The company has not received any shareholder / investors complaints during the quarter ended December 31, 2021.
- 5 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

For and on behalf of Board of Directors of Nexus Surgical and Medicare Limited

Rawi Swaroop Joshi Whole-time Director DIN: 07184085

Vasai February 14, 2022 CA SATYA PRAKASH NATANI DISA(ICAI),FAFD CA SANGEETA PAREKH

CA SURESHKUMAR YADAV

CA ARCHANA JAIN

CA ANU OSWAL

## **Limited Review Report**

Review Report to
The Board of Directors
Nexus Surgical and Medicare Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of **Nexus Surgical and Medicare Limited** for the quarter ended December 31, 2021 and for the year-to-date period from April 01, 2021 to December 31, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of

Satya Prakash Natani & Co. Chartered Accountants

Firm's Registration No.: 115438W

Satya Prakash Natani

**Partner** 

Membership No.: 048091

Mumbai

February 14, 2024

UDIN: 22048091ABZMJQ8894

Office: 505, Goyal Trade Center, Sona Cinema, Shantivan, Borivali (E), Mumbai-400 066.

Tel.: 2897 6621 Email: spnatani@gmail.com Web.: www.caspnatani.in